Introduction {#sec0005}
============

Affective disorders, with a lifetime risk of 10%--20%, are a family of serious mental disorders including major depressive disorder (MDD), bipolar disorder (BPD), and anxiety ([@bib0075]). Among them, MDD and BPD are usually classified as mood disorders ([@bib1265]). According to the surveys conducted by the World Health Organization (WHO), affective disorders will become the second leading cause of disability by the year 2020 and lead to great 'burden' worldwide ([@bib1265]; [@bib1040]).

Nitric oxide synthases (NOS) are a family of catalytic synthases, including neuronal NOS (nNOS, or NOS1), endothelial NOS (eNOS, or NOS3), and inducible NOS (iNOS, or NOS2), which synthesize the production of NO, a gas signaling molecule ([@bib0030]). The endothelial isoform, eNOS, is constitutively expressed in the endothelial cells, while the macrophage isoform, iNOS, is not constitutively expressed but is induced by cytokines ([@bib0640]; [@bib0150]). In the brain, nNOS derived NO constitutes the largest proportion of NO. The protein nNOS exhibits a bidomain structure containing a reductase domain (C-terminal) plus an oxygenase domain (N-terminal) and consists of 1434 amino acids ([@bib0145]). Overall, the oxidation of L-arginine are catalyzed by nNOS to generate citrulline and NO as products in a wide range of tissues ([@bib1700]). Specifically in the CNS, nNOS is mainly located in neurons, astrocytes, and neuroanl stem cells (NSCs) in the mammalian central nervous system (CNS) ([@bib0935]). Changes in nNOS expression have been detected in sevral CNS disorders such as MDD, BPD, anxiety, stroke, Parkinson's disease (PD), Alzheimer's disease (AD), and amytrophic lateral sclerosis (ALS) ([@bib0180]; [@bib0905]; [@bib1660]; [@bib1430]). In excitory neurons, NMDAR and nNOS are linked by postsynaptic density protein 95 (PSD95) at glutamatergic synapses, mediating the glutamate signal ([@bib0265]; [@bib0270]). Activation of nNOS depends on NMDARs-mediated calcium influx, incerasing the content of NO. Glutamate is the major excitatory neurotransmitter in the CNS. A growing body of evidence suggests that the dysfunction of glutamatergic neurotransmission is involved in the pathology of MDD, BPD and anxiety ([@bib1230]; [@bib0045]; [@bib0260]; [@bib0375]; [@bib0495]; [@bib0505]; [@bib0450]). The effects of glutamate in the CNS are mainly mediated through glutamate receptors including NMDARs ([@bib1060]).

The N-methyl-D-aspartate receptors (NMDAR) is one of the three types of ionotropic glutamate receptors. Stimulation of NMDARs results in activation of neuronal nitric oxide synthase (nNOS), an enzyme catalyzing the formation of nitric oxides (NO) from L-arginine ([@bib0490]). NMDARs are predominantly concentrated in the limbic system, a brain area that has close relationship with MDD, BPD and anxiety ([@bib1155]; [@bib0160]; [@bib0980]). It is found that the antagonists of NMDARs exhibit the property of antidepressants ([@bib1075]; [@bib1635], [@bib1640]). More importantly, clinical antidepressants such as fluoxetine, metapramine, moclobemide and desipramine bind to the NMDARs and act directly as antagonists and reduce the activity and expression of NMDAR ([@bib1435]; [@bib0985]). Ketamine, a non-competitive NMDA receptor antagonist, repeated treatment of which or at a single low dose, was proved a fast-acting antidepressant response ([@bib0375]; [@bib0465]; [@bib0560]; [@bib0580]; [@bib0995]; [@bib1445]; [@bib1610]; [@bib1665]; [@bib0880]). Besides, clinical trials demonstrated ketamine's rapid activity in patients with treatment-resistant MDD, BPD, and anxiety ([@bib0680]; [@bib1045]). Therefore, NMDAR and its down-stream signaling would be considered as the potential targets for discovery of the fast-onset antidepressant ([@bib0010]; [@bib0710]). The polymorphisms of NR1 subunit of NMDARs have a high association with BPD ([@bib1030]). Decreased expression of the NR2 subunit in the anterior cingulate cortex was found in a post mortem study of BPD patients ([@bib1590]). Additionally, *in-situ* hybridization assessment revealed that the expression of both NR1 and NR2 A subunits in the hippocampus were reduced in the patient with BPD ([@bib0990]). Furthermore, it was observed that a wide variety of NMDARs antagonists have shown anxiolytic-like effects ([@bib1230]). Converging lines of evidences suggest that NMDARs have important functions in the pathology of affective disorders and may be a novel therapeutic target ([@bib1265]; [@bib0980]; [@bib0765]; [@bib0655]; [@bib1325]; [@bib1565]; [@bib0955]). However, the high risk of neurotoxicity caused by NMDARs antagonists is concerning ([@bib1105]; [@bib0400]). In order to avoid the potential severe side effects, it is necessary to explore a safe drug target in the downstream signaling of NMDARs. Since nNOS works as a main downstream molecule of NMDARs ([@bib1035]), these studies support a potentially important role of nNOS in the pathology of affective disorders and nNOS may be a practical and more selective drug target for treatment of affective disorders. Thus, in this review we will summarize the evidence of the roles of nNOS in the pathology of MDD, BPD, and anxiety, which could assist in new drugs discovery for treating affective disorders.

NO plays an important role in the physiology of the CNS ([@bib0030]; [@bib0480]). However, it turns harmful when involved in some pathological processes mainly due to its reactivity with reactive oxygen species (ROS), forming peroxynitrite (ONOO·) which can nitrosylate extensive proteins, lipids, deoxyribonucleic acid (DNA), ribonucleic Acid (RNA), and other cell constituents ([@bib0050]; [@bib0445], [@bib0440]). Of note, biosynthesis of neurotransmitters can be regulated by NO ([@bib1460]). Additionally, hippocampal neurogenesis, neuronal plasticity, nerve growth factor synthesis, hypothalamic-pituitary-adrenal (HPA) axis activity and other targets involved in depression are modulated by NO ([@bib0570]; [@bib0140]; [@bib0195]). It has been documented that the dysfunction of NO in the brain is related to the etilogy of MDD, BPD, and anxiety ([@bib0090]; [@bib0350]; [@bib1190]). However, the function of nNOS pathway in affective disorders is not comprehensively reviewed. In the present review, we analyzed studies on the interaction between nNOS and the signal molecules involved in affective disorders and recognize that nNOS plays a critical role in the primary pathological changes of affective disorders.

nNOS expression and distribution in the CNS {#sec0010}
===========================================

More than 10 differently spliced nNOS transcripts were reported, among which three isoforms of nNOS including nNOSα, nNOSβ, and nNOSμ are the principal ([@bib0810]). In the CNS, the 160 kDa nNOSα is the predominant splice variant, accounting for the great majority of catalytic activity in the brain ([@bib1035]). A radioactive oligonucleotide in situ hybridization experiment employed the nNOSβ-specific probe indicated that nNOSβ may be responsible for the major portion of citrulline formation ([@bib0390]). The isoform nNOSμ is majorly expressed in striated muscle, important for muscle homogenates ([@bib1035]; [@bib0810]; [@bib1170]). Among the three isoforms, nNOSα is well-studied in the CNS diseases, with wide distribution in other cell types including astrocyte and neural stem cells (NSCs), not only neurons, in the brain ([@bib0180]; [@bib0930]).

In the brain, nNOS is predominantly expressed in the hippocampus, cortex, hypothalamus, DRN, amygdala, and other regions ([@bib1525]; [@bib1085]; [@bib1440]; [@bib0865]; [@bib1365]; [@bib1655]), ([Table 1](#tbl0005){ref-type="table"}), the areas of the brain related to stress and affective disorders. Almost all of the sub-regions of the hippocampus including detate gurus, hilus, CA3, CA1, and subiculum express nNOS in different cell types such as interneurons, granular neurons, and pyramidal neurons, indicating that nNOS plays an important role in the function of the hippocampus ([@bib1680]; [@bib1100]; [@bib0890]; [@bib1555]). Both the periventricular and magnocellular nucleus of the hypothalamus harbor nNOS cells expressing LepRb or Sim1 ([@bib0870]; [@bib1420]). More importantly, it has been shown that NOS directly exist in corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) neurons and modulate the secretion of CRF ([@bib1110]; [@bib1630]; [@bib0590]) ([Table 1](#tbl0005){ref-type="table"}). In the amyadala, nNOS is mainly found in the basolateral complex. Various types of neurons in different regions of the cerebral cortex also contain nNOS ([Table 1](#tbl0005){ref-type="table"}), indicating diversified functions of nNOS in the cortex. Notably, nNOS and 5-HT are co-expressed in the same neurons in different areas of the dorsal raphe nucleus (DRN) ([@bib1440]; [@bib1085], [@bib1085]; [@bib1440]; [@bib0865]; [@bib1365]), implying the interaction between nNOS and 5-HT in the biological function of DRN.Table 1The distribution of nNOS expression in the CNS.Table 1Tissue in the CNSSub-regionCell typesHippocampusCA1Pyramidal cells and interneurons ([@bib1680]; [@bib0890]; [@bib1555])CA3Pyramidal cells and interneurons ([@bib1680])Granular layerGranule cells ([@bib1680]; [@bib0890])Molecular layerInterneurons ([@bib1245])HilusGABA interneurons ([@bib1680]; [@bib0890])\
GAD67 interneurons ([@bib0725])SubiculumInterneurons ([@bib1100])HypothalamusParaventricular NucleusLepRb neurons ([@bib0870]);\
Sim1 neurons ([@bib1420]);\
CRF neurons ([@bib0590])\
8-arginine vasopressin neurons ([@bib1080])Magnocellular NucleusOxytocin neurons ([@bib1080])Supraoptic nucleusNA ([@bib1395])AmygdalaBasolateral complexGABAergic interneurons ([@bib1530]; [@bib1500])Cerebral cortexNeocortexGABAergic interneurons ([@bib1345])Prefrontal cortexInterneurons ([@bib1725]; [@bib1390])Visual cortexCalretinin- or parvalbumin-positive interneurons ([@bib0565]; [@bib0855])Entorhinal cortexNA ([@bib1100])Temporal cortexGABAergic interneurons ([@bib0115])Barrel cortexGABAergic interneurons ([@bib1180])Dorsal raphe nucleusDorsomedial area5-HT neurons ([@bib1440]; [@bib1365])Ventromedial area5-HT neurons ([@bib1440]; [@bib1365])Periventricular part5-HT neurons ([@bib0865]; [@bib1365])StriatumStriatal matrixSpiny nitregic neurons ([@bib1215])Olfactory bulbPeriglomerular regionPeriglomerular cells ([@bib0230]);\
GABAergic neurons ([@bib0275])Vomeronasal accessoryGranule cells ([@bib0785])Nasal EpitheliumOlfactory receptor neurons ([@bib1270])Basal gangliaCorpus striatumNA ([@bib0665])Locus coeruleusNANeuromelanin-containing neurons ([@bib0755]; [@bib0130]; [@bib0760])Spinal cordDorsal hornNA ([@bib0915]; [@bib0295])Cerebellar cortexMolecular layerStellate, basket, Purkinje and granule cells ([@bib0015]; [@bib0975])[^1]

The level of nNOS in other places of the brain is relatively lower ([Table 1](#tbl0005){ref-type="table"}). For instance, nNOS-expressing cells are found in the striatum, and there is evidence showing that nNOS in the striatum is implicated in the pathology of Aging ([@bib0325]), Parkinson's disease ([@bib0210]) and Huntington's disease ([Table 1](#tbl0005){ref-type="table"}) ([@bib1070]). There is also data showing that nNOS in the locus coeruleus (LC) is involved in the pathology of BPD ([Table 1](#tbl0005){ref-type="table"}) ([@bib0755]). Furthermore, nNOS-positive cells are found in the basal ganglia, olfactory bulb, and cerebellar cortex, though the role of nNOS in these tissues needs further investigation ([Table 1](#tbl0005){ref-type="table"}) ([@bib0665]; [@bib1270]; [@bib0785]; [@bib0275]; [@bib0015]). A large number of nNOS positive cells and nNOS immunoreactive axons are also reported in the spinal cord, which is involved in the pathology of pain ([Table 1](#tbl0005){ref-type="table"}) ([@bib0915]).

nNOS signaling in the brain {#sec0015}
===========================

The dimer form is the active form of nNOS, requiring tetrahydrobiopterin (BH4), heme and L-arginine binding. Although the synthesized NO from endogenous L-arginine is the principle signaling mediator of nNOS, the featured structure of nNOS contributes to its flexible signal transduction pathway ([@bib1700]; [@bib0935]). There are two non-overlapping binding sites in the structure of nNOS, including a canonical PDZ domain (residues 1--99) that binds PDZ motifs inside other proteins ([@bib0690]; [@bib0960]; [@bib1240]; [@bib0215]) and an "internal" PDZ motif (residues 100--130) that binds PDZ domains of other proteins ([@bib0255]; [@bib0645]). Neuronal NOS is an important enzyme in the downstream cascade of the NMDARs. The PDZ domain of nNOS binds to the second PDZ domain of the postsynaptic density protein-95 (PSD-95), which in turn binds to the cytosolic tail of the NMDARs ([@bib0255]) ([Fig. 1](#fig0005){ref-type="fig"}). When a large volume of glutamate is released from pre-synapse into the synaptic gap, NMDARs on the post-synaptic membrane opens in response to glutamate binding, allowing Ca^2+^ influx into the cell ([Fig. 1](#fig0005){ref-type="fig"}). The elevated cytosolic Ca^2+^ concentration is required for Calmodulin (CaM) to interact with nNOS, leading to activation of nNOS by phosphorylation of nNOS, increasing NO production. The nNOS are attached to the plasma membrane via adapter proteins such as PSD-95, creating the particulate form of nNOS with a higher probability of activation by CaM compared to soluble nNOS in the cytoplasm. However, the interaction between nNOS and CaM is blocked by the Calmodulin protein kinase (CaMKII) via phosphorylation of nNOS ([Fig. 1](#fig0005){ref-type="fig"}). The triple-complex of NMDAR/PSD-95/nNOS plays an important role in a range of normal neuronal functions including learning and memory and synaptic plasticity ([@bib0480]; [@bib0685]; [@bib0485]), as well as pathophysiological disorders of the brain such as stroke and pain ([@bib1675]; [@bib0005]; [@bib0425]). The membrane-localized nNOS further physically couples with another adapter protein called CAPON linked to DexRas 1 to regulate the nitrosylation of DexRas 1 ([@bib0690]; [@bib0395]), activating a downstream MAP kinase (MAPK) cascade and modulate nuclear transcription of cAMP-response element binding protein (CREB), N-myc proto-oncogene protein (N-Myc), nuclear factor-kappa B (NF-κB), Tumor protein (p53), and histone deacetylase 2 (HDAC2), *etc*. ([Fig. 1](#fig0005){ref-type="fig"}).Fig. 1A descriptive model for the signaling pathway of nNOS in excitatory neurons.Fig. 1

The function of nNOS is majorly mediated by the NO-activated soluble guanylate cyclase (sGC)- cyclic guanosine monophosphate (cGMP)- protein kinase G (PKG) pathway, affecting postsynaptic neuronal excitability and targeting several ion channels including sodium, voltage-gated calcium, calcium-activated and ATP-sensitive potassium, and cyclic nucleotide-gated channels, as well as AMPA receptors (AMPARs) to modulate synaptic strength ([@bib0180]). Meanwhile, NO also diffuses to presynaptic region and regulates presynaptic neurotransmitter release ([Fig. 1](#fig0005){ref-type="fig"}). Excessive amounts of NO produced under pathological conditions are associated with increased inflammation and oxidative stress reacts with superoxide anion oxygen (O2)^•^, to form ONOO^•^ ([@bib1135]). Nitrosylation including S ­ nitrosylation and nitrotyrosination of proteins are important in physiological and pathological signaling ([@bib0050]; [@bib0445], [@bib0440]). Functionally, some receptors such as NMDARs, sodium channels are inhibited by nitrosylation while other channels or receptors such as L-type calcium (Ca) channel, calcium activated potassium channel, and GABA-A receptor are activated by nitrosylation ([@bib0250]; [@bib0970]). The different effects on channels and receptors precisely regulate a wide spectrum of physiological processes including cell death and injury, synaptic function, redox response, mitochondrial function, and transcriptional control ([@bib0180]). Particularly, nNOS may represent a central component that regulates synaptic transmission and intercellular signaling, through negative regulation of the NMDARs by S-nitrosylation ([@bib0775]) ([Fig. 1](#fig0005){ref-type="fig"}). Beside of excitatory neurons, the signaling pathway of nNOS in interneurons and astrocytes are not well studied and remain unclear.

Overall, the catalytic activity, protein-protein interaction, and subcellular localization of nNOS are the key factors in its signal transduction.

Glutamate synthesized and released in the pre-synapse binds to the NMDARs at the post-synapse, leading to influx of Ca^2+^ which then activates nNOS and its signaling pathway.

Affective disorders {#sec0020}
===================

Affective disorders, mainly including MDD, BPD, and anxiety disorders, are a set of psychiatric diseases characterized by dramatic changes or extremes of mood ([@bib0075]). MDD is characterized by feelings of extreme sadness, hopelessness, and a proportion of patients have suicide attempts ([@bib1580]). The clinical medication for MDD include tricyclic antidepressants (TCAs), tetracyclic antidepressant, SSRIs, serotonin and norepinephrine reuptake inhibitors (SNRIs), dopamine reuptake blocker, 5-HTR1 A antagonist, 5-HTR2 antagonists, 5-HTR3 antagonist, monoamine oxidase inhibitors (MAOIs), and noradrenergic antagonist. Classic BPD is featured by switching of two periods of mood including depression and mania ([@bib0515]). The treatment for BPD includes lithium, an old mood stabilizer, and atypical antipsychotics with greater side effects, such as aripiprazole, risperidone, quetiapine, ziprasidone, and clozapine. Anxiety disorders are characterized by feelings of nervousness, anxiety, and even fear ([@bib0550]). Medication used for alleviating the symptoms of generalized anxiety disorder includes benzodiazepines including alprazolam, clonazepam, chlordiazepoxide, diazepam, and lorazepam, SSRIs, SNRIs, and some of the tricyclic antidepressants. Although similar symptoms and cure strategy and drugs cause difficulty in precise treatment of affective disorders, these disorders can be distinguished and divided into several subtypes according to diagnosis criteria with different treatment guidance and principle.

The pathogenesis of affective disorders involves both neurology and psychiatry; however the molecular mechanism is not fully understood. Increasing hereditary evidence shows that the affective disorders are influenced by the interaction between genetic and environmental factors ([@bib0075]). In a given genetic background, dysfunction of neurotransmitters and hormones in the brain in response to environmental factors, such as stressful life events, play a major role in the development of affective disorders ([@bib0875]; [@bib1575]; [@bib0940]; [@bib0300]). Life events, such as a traumatic event, personal loss, health problem, family issue, and alcohol or drugs abuse, can trigger the pathological changes related to affective disorders.

Two main types of treatments available for affective disorders are medication and psychotherapy ([@bib0330]). There are many different medications available for relieving the symptoms ([@bib0965]; [@bib1010]; [@bib1020]; [@bib1055]; [@bib1205]). However, the solution of affective disorder remains still impossible under current typical clinic therapy merely, driving scientists to search new therapeutic targets. The 'Monoamine-Deficiency Hypothesis', developed from clinical observations cannot fully explain the mechanism of depression ([@bib0120]). However, abnormality of monoamine level couldn't completely interpret for depression, indicating that other signal molecules may be critical in the pathological development of affective disorders. The distribution of nNOS-positive neurons in the brain, mainly in the hippocampus, cortex, hypothalamus, DRN, and amygdala ([Table 1](#tbl0005){ref-type="table"}), implies a strong link between nNOS and affective disorders. Interestingly, the interaction between nNOS and monoamine was found important in the antidepressive effect of classic antidepressants ([@bib1375]; [@bib1320]; [@bib0245]; [@bib1415]; [@bib0060]; [@bib0155]; [@bib0435]). Collectively, increasing evidences are showing that nNOS in different regions of the brain play fundamental roles in the pathology of MDD, BPD, and anxiety.

nNOS and MDD {#sec0025}
============

MDD is a chronic, recurring and potentially life threatening mental illness that causes marked diminished interest or pleasure and a persistent feeling of sadness ([@bib0100]; [@bib0675]). The diagnosis of MDD requires a distinct change of mood characterized by sadness or irritability which last a minimum of 2 weeks ([@bib0100]). Since its development in 1960 by Dr. Hamilton, the Hamilton Depression Rating Scale (HAM-D) has been widely applied to diagnose depression ([@bib0585]). The core symptom of MDD is accompanied by at least several psychophysiological changes, such as sleep disturbances, reduced appetite, slowed thinking, suicidal thoughts, and angry outbursts ([@bib0100]).

Numerous theories of the etiology of depression have been developed. The 'Monoamine-Deficiency Hypothesis', an early milestone in the pathophysiology of depression, is demonstrated by the facts that monoamine is decreased in the brain and antidepressants effectively recover it ([@bib1005]). However, serious gaps and limitations have been revealed in the 'Monoamine-Deficiency Hypothesis'([@bib0120]; [@bib1005]). For instance, it takes at least 3--4 weeks to exert antidepressant effects while the concentrations of monoamine increase rapidly after antidepressant treatment. Despite this, only a subset of patients shows recovery after antidepressant treatment by increasing the concentration of monoamine. Hyperactivity of the HPA axis is also observed in the majority of patients with depression, as manifested by hyper-secreted CRF from the hypothalamus and adrenal hyper-responsiveness to circulating adrenocorticotropic hormone (ACTH) ([@bib0300]; [@bib1160]; [@bib1585]). Over the years, the hypotheses on the pathophysiology of depression and on the molecular mechanisms of antidepressants have greatly extended ([@bib1580]; [@bib0120]). Depression is associated with impairments of structural plasticity and cellular resilience. Numerous preclinical and clinical studies have shown that signaling pathways involved in regulating cell survival and cell death are long-term targets for the actions of antidepressants, including brain derived neurotrophic factor (BDNF), CREB, and molecules regulating adult hippocampal neurogenesis ([@bib0385]; [@bib0805]). Furthermore, the glutamatergic system and gamma aminobutyric acid (GABA) system also have been demonstrated to be involved in the pathophysiology of depression ([@bib0955]; [@bib0950]).

The major function of nNOS is synthesis of NO. There are various evidences that have demonstrated an imperative role of NO derived from nNOS positive neurons in MDD ([@bib0090]; [@bib0350]; [@bib0020]; [@bib0630]; [@bib1625]). Neurons expressing nNOS are predominantly located in the hippocampus, cortex, hypothalamus, DRN, amygdala ([@bib1525]; [@bib1085]; [@bib1440]; [@bib0865]; [@bib1365]; [@bib1655]), strongly implicated in MDD ([Table 1](#tbl0005){ref-type="table"}). More and more studies revealed indispensable roles of nNOS-NO pathway in the etiology and treatment of MDD, which are discussed in the following sessions.

Antidepressant properties of nNOS inhibitors {#sec0030}
============================================

More and more clinical and pre-clinical studies strongly suggest the implication of the NO cascade in the pathology of depression ([@bib0350]; [@bib1535]; [@bib1115]; [@bib1720]; [@bib0720], [@bib0715]; [@bib0340]; [@bib0040]; [@bib0595], [@bib0605]). Jefferys and Funder showed that L*-N-*arginine methyl ester or N^G^-nitro-L-arginine methyl ester (L-NAME), a type of general NOS inhibitor, decreased immobility of rats in the Porsolt forced swimming test, which was reversed by pre-treatment with L-arginine (the NOS substrate) ([@bib0705]). Both acute and chronic treatment of L-NAME produced antidepressive-like response in FST ([@bib0595]). N^G^-monomethyl-L-arginine (L-NMMA), another NOS inhibitor, also elicited antidepressive-like effect in FST ([@bib0595]). In line with this finding, studies found that NG-nitro-L-arginine (L-NA or L-NNA), another type of non-preferential NOS inhibitor, resulted in antidepressant-like effects in the forced swimming test (FST) and augmented the behavioral effect of antidepressants ([@bib0500]; [@bib0750]; [@bib0600]) ([Table 2](#tbl0010){ref-type="table"}). Co-treatment with the non-selective 5-HT receptor antagonist metergoline, preferential 5-HTR2 A antagonist ketanserin, or the 5-HTR2C antagonist RO-430440, but not 5-HTR1 A antagonist WAY 100,635 or the 5-HTR1B antagonist GR 127935, attenuated the L-NA-induced reduction in immobility in FST ([@bib0500]). Administration of lipopolysacharide (LPS) is a model of depression in rodents. It was found that NOS inhibitors, including L-NAME, aminoguanidine, and sildenafil prevented the LPS-induced depression-like behavioral and neurochemical alterations ([@bib1455]).Table 2Antidepressant properties of nNOS inhibitors.Table 2DrugsSpeciesConditionTreatmentTest (post treatment)MechanismL-NAMERatPhysical state50 mg/kg, i.p., 1 timeFST (30 min)Nitric Oxides ([@bib0705])MicePhysical state10 mg/kg, i.p., 1 timeFST (1 hour)Nitric Oxides ([@bib0595]; [@bib1715])MicePhysical state5mg/kg, i.p., 1 timeFST (1 hour)Nitric Oxides ([@bib0225])MicePhysical state5mg/kg, i.p., 1 timeFST (1 hour)5-HTR1 A/5-HTR1B ([@bib0225])MicePhysical state5mg/kg, i.p., 1 timeFST (1 hour)Adrenergic system ([@bib0225])MiceLPS treatment30 mg/kg, i.p., 1 timeFST, SPT (24 hours)NO-cGMP pathway ([@bib1455])MiceClonidine treatment10 mg/kg, i.p., 1 timeFST (1 hour)NA ([@bib0225])MiceReserpine treatment10 mg/kg, i.p., 1 timeFST (1 hour)NA ([@bib0225])L-NMMAMicePhysical state30 mg/kg, i.p., 1 timeFST (1 hour)Nitric Oxides ([@bib0595])L-NARatPhysical state20 mg/kg, i.p., 1 timeFST (1 hour)5-HT ([@bib0600])RatPhysical state10 mg/kg, i.p., 1 timeFST (1 hour)Neuronal activation in the\
DG, CA1, and DRN ([@bib1340])MicePhysical state1 mg/kg, i.p., 1 timeFST (1 hour)Nitric Oxides ([@bib0750])MicePhysical state10 mg/kg, i.p., 1 timeFST (5 or 24 hours)5-HT, 5-HTR2 A, 5-HTR2C ([@bib0500])7-NIRatPhysical stateIntrahippocampal injection, 100nmolFST (30 min)Nitric Oxides in\
the dorsal hippocampus ([@bib0730])RatPhysical state30 mg/kg, i.p., 1 timeFST (1 hour)5-HT ([@bib1360])RatPhysical state20 mg/kg, i.p., 1 timeFST (1 hour)5-HT ([@bib0600])MicePhysical state50 mg/kg, i.p., 1 timeFST (50 min)Nitric Oxides ([@bib1520])MicePhysical state50 mg/kg, i.p., 7 daysFST (1 hour)Hippocampal 5-HT ([@bib0290])MiceChronic stress30 mg/kg, i.p., 4 daysCoat State, FST, TST\
(1 month)Hippocampal neurogenesis ([@bib1670])MiceCorticosterone30 mg/kg, i.p., 7 daysFST, TST, SPT (1 month)Glucocorticoids receptor ([@bib1680])MiceLearned helplessness30 mg/kg, i.p., 7 daysLH development (24 hours)Hippocampal BDNF level ([@bib1340])TRIMRatPhysical state50 mg/kg, i.p., 1 timeFST (50 min)5-HTR1 A ([@bib1480])RatPhysical state50 mg/kg, i.p., 1 timeFST (1 hour)Neuronal activation in the\
DG, CA1, and DRN ([@bib1340])MicePhysical state50 mg/kg, i.p., 1 timeFST (50 min)Nitric Oxides ([@bib1520])MiceChronic stress30 mg/kg, i.p., 35 daysCoat State, Splash test\
(3 weeks)Nitric Oxides ([@bib1050])NPARatAcute stressIntrahippocampal injection, 0.01 pmolFST (1 hour)Hippocampal 5-HTR1 A ([@bib0650])RatAcute stressIntrahippocampal injection, 0.001 nmolFST (24 hours)NO-sGC pathway\
in the dorsal hippocampus ([@bib1255])[^2]

Selective nNOS inhibitors produced acute antidepressant-like effects in behavioral measurement ([@bib1520]; [@bib0730]; [@bib1360]). For instance, 7-nitroindazole (7-NI), a preferential inhibitor of nNOS, and 1-(2-trifluoromethylphenyl)imidazole (TRIM), a stronger preferential inhibitor of nNOS, decreased immobility time in the FST ([@bib1520]; [@bib0730]; [@bib1360]; [@bib1480]). Moreover, 7-NI augmented the behavioral effects of imipramine and fluoxetine in FST ([@bib0605]). Studies showed an increase in Fos expression in several brain regions after stress which were attenuated by 7-NI similar to fluoxetine and venlafaxine, suggesting that these drugs share common neurobiological substrates \[[@bib1360]). Consistently, acute stress-induced increase in c-FOS immunoreactivity in the brain was reduced following treatment with L-NA or TRIM ([@bib1340]). Additionally, 7-NI administration altered the expression of genes related to transcription in the cAMP response element-binding pathway, which possibly account for the antidepressant-like effects induced by nNOS inhibition ([@bib0405]). The antidepressive property targeting nNOS was also documented by the effect of Nω-propyl-L-arginine (NPA), another preferential nNOS inhibitor ([@bib0490]; [@bib1255]). Notably, microinjection of NPA into the dorsal hippocampus induced dose-dependent antidepressant-like effects, which were counteracted by a 5 H TR1 A antagonist ([@bib0650]). It was recently shown that acute stress exposure increased nNOS expression, the concentration of NO in the hippocampus, and both NPA and \[1*H*-\[1,2,4\]Oxadiazole\[4,3-*a*\]quinoxalin-1-one\] (ODQ), an inhibitor of sGC, induced an antidepressant-like effect \[[@bib1255]; [@bib0615]; [@bib1175]; [@bib0355]). Carboxy-PTIO (c-PTIO), a type of NO scavenger, produced antidepressant-like effects in the FST ([@bib1175]; [@bib0355]; [@bib1200]). Interestingly, hippocampal NO was shown to play a role in the antidepressant-like effect of ketamine ([@bib0895]). Our lab found that nNOS knockout mice possess an antidepressant-like phenotype ([@bib1670]). More importantly, we found that chronic stress caused overexpression of nNOS in the hippocampus and inhibition of nNOS activity reversed chronic stress-induced depressive behaviors([@bib1680], [@bib1670]). Repeated treatment with 7-NI (30 mg/kg), at which dose increased BDNF protein levels in the hippocampus, attenuated learned helplessness development ([@bib1340]). Although the selectivity of 7-NI was concerned, the dose exerting antidepressive effect (30 mg/kg) did not changed the enzymatic activities of iNOS and eNOS ([@bib1670]). Additionally, it was shown that repeated administration of TRIM improved the depression behavior of mice exposed to chronic stress ([@bib1050]).

Altogether, extensive evidence indicates that the nNOS-NO-sGC pathway plays an important role in depression-related behavior and the signaling of 5-HT in the hippocampus is implicated in the antidepressive effect of nNOS inhibitors ([Table 2](#tbl0010){ref-type="table"}).

nNOS as the target of stress {#sec0035}
============================

Life stress is a primary cause of depression ([@bib0095]). The cortex, hippocampus, amygdala, and the HPA axis are all involved in the pathology of depression ([@bib0820]; [@bib1335]). Increasing data suggest that life stress leads to enhancement of nNOS expression and activity in these brain regions. Acute restraint stress evoked an increase in the content of NO₂/NO₃ in the dorsal hippocampus ([@bib1025]). Five days after a single or repeated restraint stress, there was an additional increase in NADPH- or nNOS-positive neurons in the CA1, CA3 sub-region of the hippocampus, and the entorhinal cortex ([@bib0380]). In addition, 21 days CMS exposure increased nNOS expression in all fields of the hippocampus (CA1, CA3, DG, and subiculum) ([@bib1680], [@bib1685]). The total hippocampal nNOS activity, nNOS protein levels and mRNA expression were increased after stress in the Flinders rat, a genetic animal model of depression ([@bib1545]).

After 2 h of immobilization stress, nNOS mRNA expression in the anterior pituitary and adrenal cortex was up-regulated with 1.5 and 2-fold respectively ([@bib0790]). The nNOS mRNA signals in hypothalamic paraventricular nucleus (PVN) significantly increased after the stress for 6 h ([@bib0740]). However, some studies showed that NOS^+^ cell density and number in the PVN were significantly decreased in rats after chronic stress, and in humans with depression ([@bib0470]; [@bib0110]; [@bib0315]). Thus, how nNOS changes in the PVN after stress or in patients with depression require more evidence. Acute restraint stress induced a significant increase in the density of neurons expressing NADPH-d and nNOS in the amygdala nuclei ([@bib0380]). In addition, a significant increase of NOS enzyme activity in the anterior pituitary, adrenal cortex, and adrenal medulla was observed in the stressed animals (immobilization of 6 h) as compared to non-stressed control rats ([@bib0790]; [@bib0825]).

NO primarily mediates the biological function of nNOS ([@bib1700]). Researchers provide evidence that NO mediates the function of nNOS after stress exposure. An early study found elevated plasma nitrate levels in patients with major depression compared with both patients with anxiety disorder and normal control subjects ([@bib1425]). It was also showed that plasma NOx levels among suicidal depressive patients are higher than among non-suicidal depressive patients and normal controls ([@bib0780]). More specifically, stress caused activation of NO-producing neurons in the brain of rat ([@bib0825]). Furthermore, following treatment of depressed patients with paroxetine, levels of serum nitrate and nitrite, both of which are degradation products of NO, was significantly reduced. The same authors showed that paroxetine indeed inhibited conversion of L-arginine to citrulline and NO in vitro ([@bib0780]). Consistently, NO levels in the plasma were significantly increased in rats exposed to chronic unpredictable stress ([@bib0470]). Our previous work demonstrated that hippocampal injection of SIN-1 induced depressive behavior in mice and clearance of NO by c-PTIO in the hippocampus counteracted chronic stress-induced depressive behavior ([@bib1680]). Collectively, increasing evidences show that nNOS located in several regions of the CNS such as the hippocampus, hypothalamus and pituitary is reactive to stress stimuli, indicating an important role of nNOS in the development of MDD.

The role of nNOS in serotonergic signaling in depression {#sec0040}
========================================================

The monoamines including 5-HT, NA, and DA are involved in the pathogenesis of affective disorders ([@bib1335]; [@bib0660]). Particularly, the role of the 5-HT pathway is well established and recognized in the pathogenesis of depression ([@bib0200]). A deficiency of 5-HT was discovered very early from post-mortem studies of patients with major depression \[[@bib0660]; [@bib1330]; [@bib0065]). Based on this result, several types of antidepressants increasing the concentration of 5-HT in the synaptic cleft were developed. In the brain, several places including the hippocampus, amygdala, frontal cortex, and hypothalamus (post-synaptic tissues) receive serotonergic input from the DRN (pre-synaptic tissues). The dysfunction of serotonergic neurons is found both in the pre-synaptic tissues and post-synaptic tissues. The central theory of depression supported by these findings is called 'Monoamine-Deficiency Hypothesis' or 'Monoamine theory'. Nitric oxide is ubiquitously synthesized by nNOS in these tissues, playing a fundamental role in extensive physiological and pathological processes. The coexistence of the two transmitters offers the high probability that they act together in depression.

A growing body of evidence suggest that nNOS regulates the synthesis, release, and uptake of 5-HT. Tryptophan hydroxylase (TH), the rate-limiting enzyme in biosynthesis of 5-HT, is inactivated by ONOO·, which is mediated by sulfhydryl oxidation, in a concentration-dependent manner ([@bib0835]; [@bib0840]; [@bib0055]). In addition, NO donor S-nitroso*-N-*penicillamine (SNAP) was shown to decrease 5 H T release in the raphe nucleus but increase release in the frontal cortex ([@bib1375]). Both local infusion of 7-NI into the hippocampus and systemic administration significantly increased extracellular level of 5-HT ([@bib1320]). Consistently, Chiavegatto et al revealed that nNOS knockout mice had increased levels of 5-HT in several brain regions regulating emotion, including cerebral cortex, hypothalamus, hippocampus, and amygdala ([@bib0245]). In contrast, administration of L-Arg, the substrate for catalyzing NO, decreased the level of 5-HT in the hippocampus ([@bib1415]). Sodium nitroprusside (SNP), a NO donor, inhibited the uptaking of 5-HT into synaptosomes in the rat brain without effecting the 5-HT transporter ([@bib0060]). However, other types of NO donors such as (*Z*)-1-\[*N*-methyl-*N*-\[6-(*N*-methylammoniohexyl)-amino\]\]diazen-1-ium-1,2-diolate (MAHMA/NO) and 5-amino-3-(4-morpholinyl)-1,2,3-oxadiazolium chloride (SIN-1) inhibited 5-HT uptake by SERT in COS-7 cells expressing human SERT ([@bib0155]). In an early study, it was shown that SERT was transformed into an inactive form to reduce 5-HT in the presence of 3-morpholinosydnonimine, a nitric oxide donor or endogenous nitric oxide synthase was activated ([@bib0435]). The activation of NMDA receptors has been substantially linked to the production of the signaling molecule NO in the CNS ([@bib0480]). Previous studies demonstrated that the NMDA receptor antagonists, MK-801 and D-AP5, increased extracellular levels of 5-HT and DA in the ventral hippocampus *in vivo* ([@bib1560]). Thus, it is possible that endogenous NO functions through negative control of the levels of 5-HT in the hippocampus. Furthermore, the antidepressive effect of inhibition of NO synthase depends on the level of 5-HT ([@bib0605], [@bib0600]). In the hippocampus, postsynaptic 5-HTR1 A is an important signal mediator of 5-HT ([@bib1655]). Post-mortem studies find diminished 5-HTR1 A numbers and lowered receptor affinity in the hippocampi of depressed suicide victims. Stress and high concentration of glucocorticoid similar to the level under stressful conditions stimulates a great quantity of NO production by up-regulating nNOS expression and activity in the hippocampus ([@bib1680]). Both glucocorticoid and chronic stress also have been shown to induce downregulation of 5-HT~1A~ receptor density and messenger RNA (mRNA) content in the hippocampus. Additionally, our research found that NO donator DETA/NONOate (100 μM) depressed hippocampal 5-HTR1 A expression *in vitro* and *in vivo* (data not published). These data together let us postulate that high concentration of glucocorticoids responding to the stimulation of stressful life events enhance nNOS function in the hippocampus. Therefore, endogenous NO derived from nNOS under chronic stressful stimuli in the hippocampus may participate in the pathophysiology of depression by negatively regulating the 5-HT pathway ([Fig. 2](#fig0010){ref-type="fig"}).Fig. 2The interaction between nNOS and serotonergic signaling in depression.Fig. 2

Interestingly, nNOS in turn works in downstream of the 5-HT cascade. Activation of hippocampal 5-HTR1 A inhibits postsynaptic Ca^2+^ influx through the NMDARs. Serotonin 5 H TR1B agonists abolished NMDAR-evoked enhancement of NOS activity. Administration of serotonergic antidepressants decreased hippocampal nNOS activity ([@bib1540]; [@bib0920]). Interestingly, other lines of antidepressant targeting NA and DA also involved in suppression of NOS ([@bib0815]; [@bib1120]). Methylene blue with structural similarities to tricyclic antidepressants had antidepressant properties. It was also found that methylene blue treatment reduced hippocampal nitrate levels ([@bib0610]). The antidepressant-like effect of bupropion \[(+/-)-alpha-t-butylamino-3-chloropropiophenone\], a dopamine reuptake inhibitor, was prevented by pretreatment with L-arginine, the substrate for nitric oxide synthase. Additionally, pretreatment of mice with 7-nitroindazole potentiated the effect of bupropion ([@bib0345]). Treatment with nNOS inhibitor, 7-nitroindazole, augmented the behavioral effects of imipramine and fluoxetine, respectively ([@bib0605]). The antidepressant-like effect of venlafaxine (8 mg/kg, i.p.) was prevented by pretreatment with L-arginine (750 mg/kg, i.p.), the substrate for nitric oxide synthase, demonstrating that the antidepressant-like effect of venlafaxine in the FST involved an interaction with the L-arginine-NO-cGMP pathway ([@bib0720], [@bib0715]; [@bib0340]). An article found that treatment with 1-(2-trifluoromethylphenyl)-imidazole (TRIM) (20 mg/kg), a nNOS inhibitor**,** augmented the behavioral effect of tricyclic antidepressant imipramine, selective serotonin re-uptake inhibitor (SSRI) citalopram and fluoxetine or selective serotonin reuptake enhancer tianeptine ([@bib1475]). Although pretreatment with L-arginine counteracted the antidepressant-like effect of imipramine, venlafaxine, bupropion but not fluoxetine, our research revealed that the blockage of nNOS accounted for the modulation of anxiety-related behavior of fluoxetine ([@bib1655]([@bib0815]).

DRN as the resource of 5-HT is critically linked to the occurrence of depressive symptoms and the effects of antidepressants ([@bib1385]). However, the role of DRN in depression is completely different from the hippocampus. In the DRN, 5-HT reduces the firing rate of neurons by stimulating the 5-HTR1 A which serves as the predominant autoreceptor, implicated in mental illness ([@bib0025]). Higher raphe autoreceptor binding and expression are detected in patients with depression and in post-mortem raphe tissue from depressed suicide victims ([@bib1405]; [@bib1410]). Moreover, these autoreceptors desensitized after 2--3 weeks of antidepressant treatments ([@bib0540]). A recent study demonstrates that 5-HT1 A autoreceptor levels determine vulnerability to stress and response to antidepressants ([@bib1235]). A large number of nNOS immunoreactive cells co-labeled with 5-HT or SERT are found in the DRN ([@bib0220]; [@bib0910]). Moreover, a study found that 7-NI, a selective nNOS inhibitor, decreased raphe 5-HT release with a concomitant increasing in the frontal cortex. Chanrion et al. found that nNOS had a physical association with the SERT by PDZ domain, reducing SERT activity in DRN ([@bib0215]). The expression of nNOS or the interaction between nNOS and SERT in the DRN may be regulated by elevated glucocorticoids after stress, accounting for the dysfunction of the postsynaptic serotonergic pathway ([Fig. 2](#fig0010){ref-type="fig"}).

This model describes the potential role of the interaction between nNOS and serotonergic signaling in depression. Increased glucocorticoids after stress arrive at the hippocampus and DRN via circulation. In the hippocampus, glucocorticoids up-regulate the expression of nNOS, causing reduced postsynaptic 5-HT~1A~R content. In the DRN, glucocorticoids modulate the 5-HT release by influencing the interaction between nNOS and SERT.

nNOS in the hyperactivity of HPA axis {#sec0045}
=====================================

The HPA axis is a multifaceted regulatory system that integrates neuronal and endocrine function ([@bib0305], [@bib0310]). It comprises the tissues of the hypothalamus, pituitary and adrenal cortex, and the associated regulatory inputs, releasing factors and hormones. In brief, the neurosecretory cells of the PVN of the hypothalamus secrete CRF and arginine vasopressin (AVP) into the circulatory system of the pituitary stalk. These hormones induce the release of ACTH from the anterior lobe of the pituitary into systemic circulation. In turn, ACTH, promotes the release of the glucocorticoids (cortisol in human, corticosterone in rodent) from the adrenal cortex ([@bib0945]). The effects of glucocorticoids are mediated mainly by two types of intracellular, specialized steroid receptor family subtypes ([@bib0305]): type I, the high-affinity mineralocorticoid receptor (MR), and the type II, low-affinity glucocorticoid receptor (GR). Decreased levels of GR in the hippocampus are thought to be the primary etiology of HPA axis hyperactivity in depression. Hyperactivity of the HPA axis is a characteristic feature of depressive illness. New data suggested an important role of the nNOS-NO pathway in HPA axis hyperactivity ([@bib1680]).

The hippocampus is the primary negative regulator of HPA axis activity in the brain ([@bib0695]). The loss of this negative control contributes to HPA axis hyperactivity after chronic stress ([@bib0635]). Glucocorticoids mediate chronic stress-induced hippocampal nNOS overexpression via activating MR ([@bib1680]; [@bib1705]). In turn, hippocampal excessive NO significantly down-regulates local GR expression through soluble guanylate cyclase (sGC)/cGMP and ONOO·/extracellular signal-regulated kinase signaling pathways ([@bib1680]) ([Fig. 3](#fig0015){ref-type="fig"}). By creating transgenic mice blocking neurogenesis, Snyder et al. showed that killing newborn neurons in the adult hippocampus causes elevated HPA axis activation, contributing to the etiology of depression ([@bib1380]). Therefore, overexpressed nNOS in the DG may lead to HPA hyperactivity via reduction of hippocampal neurogenesis.Fig. 3The role of nNOS in regulating the HPA axis.Fig. 3

The PVN of the hypothalamus, which drives the HPA axis, provides a negative feedback of the activity of the HPA axis. The mRNA of nNOS is detected in the PVN in rats by *in situ* hybridization histochemistry ([@bib0850]). The NO generated in the PVN is involved in regulating HPA axis activity ([@bib1220]). Direct intracerebroventricular injection of NO donor 3-morpholino-sydnonimine (SIN-1) up-regulated transcription of CRF and vasopressin in the PVN, causing increased releasing of adrenocorticotropic hormone (ACTH) ([@bib0860]). In contrast, intracerebroventricular injection of S-nitroso*-N-*acetylpenicillamine (SNAP), which spontaneously breaks down to form NO, caused a transient dose-related decrease in the plasma vasopressin concentration ([@bib1125]). Administration of 7-nitroindazole (7-NI), a specific neuronal inhibitor of nNOS abolished the stimulatory action of CRF on ACTH ([@bib0460]). However, no evidence shows that excessive amount of NO is produced in the PVN in patient with MDD or in animal model of depression. While the expression level of nNOS mRNA is up-regulated by nociceptive and endotoxin stimulation, the nNOS expression in the PVN is not altered by stress ([@bib1705]; [@bib1485]). Although glucocorticoids elevated throughout the body including the hippocampus and the hypothalamus, nNOS in the PVN of the hypothalamus does not contribute to HPA axis hyperactivity due to a low level of MR in the PVN compared with the hippocampus ([@bib1705]) ([Fig. 3](#fig0015){ref-type="fig"}).

This model describes the mechanism of the different roles of glucocorticoids in the hippocampus and hypothalamus in modulation of the HPA axis. Acute stress-stimulated glucocorticoids bind to MR in the hippocampus, up-regulating nNOS expression and NO production. The excessive NO down-regulates GR via the sGC/cGMP pathway, impairing the negative feedback modulation of the synthesis of CRF in PVN neurons in the hypothalamus. However, glucocorticoids in the hypothalamus exert negative regulation on the synthesis of CRF in PVN neurons due to a lack of MR content in the hypothalamus.

The role of nNOS in neurogenesis: implication in depression {#sec0050}
===========================================================

In the last decade, it has been shown that neurogenesis persistently occurs mainly in two regions of adult brain: the subventricular zone (SVZ) of lateral ventricle (LV) and the subgranular zone (SGZ) of the hippocampus ([@bib0900]; [@bib0525]). Clinical studies suggest decreased hippocampal volume which was consistent with decreased neurogenesis and neuron degeneration in patients with depression ([@bib1280]). The causal relationship between hippocampal neurogenesis and depression is supported by multiple aspects of research. (i) Different types of stress cause reduced neurogenesis in the DG of the hippocampus. (ii) Almost all antidepressant therapies stimulate the hippocampal neurogenesis. (iii) Hippocampal neurogenesis is required for the behavioral effects of antidepressant ([@bib1275]; [@bib0625]; [@bib1400]; [@bib1285]). Therefore, in recent years, decreased hippocampal neurogenesis is considered a common pathway of the etiology of depression. The molecules involved in the modulation of hippocampal neurogenesis may be a novel target for developing antidepressant in the future.

nNOS is an endogenous factor that dampens the neurogenesis in the adult brain ([@bib1140]). The number of new cells generated in the hippocampus is strongly augmented in nNOS knockout mice([@bib1670]; [@bib1140]). Administration of nNOS inhibitors increases proliferation of neural stem cells (NSCs) and survival rate of newborn neurons in the adult hippocampus ([@bib1670]; [@bib0455]; [@bib0925]). The antidepressant effects of nNOS inhibition requires hippocampal neurogenesis ([@bib1670]). Chronic stress up-regulates the expression of nNOS in the hippocampus ([@bib1670]). Overexpression of nNOS-induced reduction in hippocampal neurogenesis contributes to the depressive behavior after chronic stress ([@bib1670]). It has been shown that glucocorticoids decreases new cell formation in the hippocampus ([@bib0185]; [@bib0190]; [@bib0530]). The elevation of corticosterone, the glucocorticoids in rodents, accounts for the nNOS overexpression in the hippocampus induced by stress ([@bib1680]). Corticosterone represses the proliferation of progenitor cells in the hippocampus in part through increased nitric oxide formation ([@bib1185]).

Telomerase, which maintains the length of telomere by adding DNA bases, is crucial for prolonged persistence of stem cells ([@bib1250]; [@bib1290]; [@bib1695]). Telomerase reverse transcriptase (TERT) knockout mice exhibit aggressive and depressive phenotypes ([@bib1690]). Inhibition of TERT activity by 3′-azido-deoxythymidine (AZT) generates depression-like behavior and suppresses hippocampal neurogenesis. Meanwhile, overexpression of TERT exerts antidepressant-like effect, which is blocked by the disruption of hippocampal neurogenesis via X ray-irradiation ([@bib1685]). Most notably, repression of TERT catalytic activity counteracts the antidepressant-like effects of nNOS inhibition ([@bib1670]). It is possible that nNOS interacts with TERT in regulating hippocampal neurogenesis and depressive mood.

The role of nNOS in depression: the gender difference {#sec0055}
=====================================================

Neurological illnesses, such as MDD, Alzheimer's disease (AD), anxiety disorders, schizophrenia, stroke, autism, and addiction, show sex differences in their incidence ([@bib1350]; [@bib0800]; [@bib0700]). Sexual dimorphism including behavioral differences, anatomic characteristics, and molecular distinctions generally exists in the brain of different genders \[[@bib0700]; [@bib0510]). These substantial differences underlie the sex gap in neurological disorders ([@bib0420]; [@bib0240]). Markedly, men and women exhibit significant sex differences in the development of depression and anxiety disorder ([@bib1165]). Notably, epidemiological investigations found that the prevalence of MDD for women is much higher for men ([@bib0520]). Gender differences were demonstrated in both monoamine transmitter system and HPA axis, which may be the fundamental bases for differential susceptibility to MDD. Sex differences in monoaminergic changes, including serotonin, norepinephrine as well as dopamine, and their receptors expression and binding were observed between male and female rats ([@bib0420]; [@bib1650]; [@bib0335]; [@bib0105]; [@bib1195]; [@bib0085], [@bib0080]). Pronounced sex differences in several aspects of basal HPA axis function were documented: 1) Higher secretion and concentration of corticosterone was detected in females; 2) Females exhibited a greater duration of HPA in response to stressors ([@bib1095]; [@bib1470]; [@bib1315]). Although extensive sex dimorphism in gene expression levels in the rodent brain were observed ([@bib1605]), the underlying molecular mechanisms for gender difference in MDD are not well characterized.

Sex hormones including testosterone and estrogen contribute to the mental state via androgen receptor (AR) and estrogen receptor (ER) in different gender ([@bib0410], [@bib0415]). Interestingly, it was found that estrogen rather than testosterone determined the gender difference in the expression level of nNOS. An early study found that estrogen stimulated the expression of nNOS and the production of NO in human neutrophils, whereas a reduction of nNOS in the adult hippocampus was detected after estrogen treatment in later studies ([@bib0475]; [@bib0545]; [@bib0670]). It was shown that ERα involved in the regulation of nNOS in preoptic area while ERβ was responsible for the nNOS expression change in the hippocampus \[[@bib0670]; [@bib1310]). The regulation of nNOS by estrogen may be involved in the estrogen-mediated neuroprotective effect([@bib1550]). Several researches demonstrated that chronic stress increased nNOS expression and activity in the hippocampus of male mice and rat, contributing to stress-induced depressive behavior ([@bib1670]; [@bib1545]; [@bib0235]). In contrast, the expression of nNOS in the hippocampus was diminished after chronic stress in female mice, accounting for stress-related deficit in learning and memory ([@bib1145]). In our lab, Hu et al found a much higher basal level of NO in the hippocampus of male mice than female mice \[[@bib0670]). The diversity was caused by different expression level of nNOS in the hippocampus, which due to the repressive regulation of nNOS expression by estrogen via ERβ, accounting for the sex difference in depression-like behaviors \[[@bib0670]). Additionally, it was shown that endogenous estradiol promoted NMDA receptor/PSD-95/nNOS coupling in the hypothalamic preoptic region of adult female rats ([@bib0280], [@bib0285]). Interestingly, another study showed that acute stress increased the expression of nNOS in the hippocampus of female but not male rats ([@bib0770]). These evidences indicate that nNOS is an important down-streamer of endogenous estrogen signaling, contributing to the modulation of neural function by the female sex hormones.

nNOS and BPD {#sec0060}
============

BPD, also known as manic-depressive illness, is characterized by recurrent shifted episodes of mania and depression as well as changes in psychovegetative function and cognitive performance, and it is one of the most severely debilitating of affective illnesses ([@bib1305]). BPD affects more than 1% of the world's population and is one of the leading causes of disability among young people ([@bib0535]). According to the longitudinal course, BPD is classified into four basic types including Bipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder, and other specified and unspecified bipolar and related disorders. Although depressive symptoms of BPD and MDD are diagnosed by the same HAM-D, certain features are used to discriminate them. More frequent depressive episodes, shorter duration of sadness, abrupt onset and offset and earlier onset age are characterized in BPD ([@bib0535]). Compared with MDD, the key manic symptoms of BPD, including extremely energized, elation, grandiosity, and increased goal activity, is unique.

The understanding of the neurobiological underpinnings of BPD is elucidated by preclinical and clinical researches. The monoamine neurotransmitters are implicated in the etiology of bipolar disorder. Similar abnormalities of the serotonergic and dopamine system in depression have been found in some studies of BPD ([@bib0515]; [@bib1645]). However, increased noradrenergic function has been observed in mania ([@bib0515]). Interestingly, significant reductions in cortex GABA levels are only detected in depression, not in BPD ([@bib1260]; [@bib0830]). Chronic treatment with lithium increases uptake of glutamate at the synaptosome in mice ([@bib0360]) and reduces glutamate-induced and NMDA-mediated excitatory toxicity ([@bib1065]). Hyperactivity of the HPA axis is also detected in many patients with BPD ([@bib1620]).

Altered NO signaling has been associated with the pathophysiology of BPD ([@bib0070]). Significantly lower level of NOx- including NO~2~- and NO~3~- levels were observed in peripheral blood of patients suffering from BPD ([@bib0795]). Consistently, another clinical study reported that patients with BPD showed reduced NOS activity in platelets compared with health volunteers ([@bib0430]). Additionally, lithium, a classic medicine for treatment of BPD, increased the level of NO in patients with BPD during depressive episodes ([@bib0320]). However, contrary results were observed by other groups, reporting that the value of plasma NO levels and total nitrite level in the BPD patients were higher than those of controls ([@bib1295]; [@bib1615]). Especially, elevated serum NO was detected in patients with BPD in euthymic phase ([@bib1300]). Thus, the correlation between NO in the blood and BPD requires more study. Nevertheless, NO metabolites in the plasma may serve as biomarkers for BPD.

The LC is a nucleus in the brainstem involved in sympathetic effects during stress. The LC comprises the largest group of NA containing neurons in the mammalian brain and the number of NE neurons is reduced in depressed bipolar suicides ([@bib1570]). The LC also harbors a high density of NMDARs ([@bib0035]; [@bib1495]), activating which result in higher activation of nNOS. It was found that the amounts of NR2C subunit of NMDAR were significantly higher in the LC of patients with BPD, implying a role of nNOS in BPD. Indeed, nNOS locates in norepinephrinergic neurons in the LC, generating NO, suggesting the existence of a glutamate/nitrergic transduction pathway in monoamine neurotransmitter neurons ([@bib0125]). A postmortem study suggested that nNOS protein level in the LC of depressive subjects is significantly lower than controls ([@bib0755]). Similarly, a lower number of nNOS-immunoreactive neurons was detected in the LC of postmortem human suffered from BPD than healthy controls ([@bib0125]; [@bib0130]). However, there is lack of correlation between nNOS gene expression and the occurrence of BPD ([@bib1355]). The nucleotide polymorphism of rs41279104 in nNOS gene had been shown no significant association with BPD ([@bib1090]). These sparked reports indicate that the impairment of nNOS may due to cell loss rather than genetic level alteration. The literature is poor, future research is necessary to elucidate the mechanisms underlying the function of nNOS in the LC in the pathogenesis and etiology of BPD. Collectively, all current data strongly suggest a nNOS-related dysregulation of the nitrergic system in the LC related to the pathology of BPD.

nNOS and Anxiety {#sec0065}
================

Anxiety is a crucial and adaptive behavioral response to dangerous situations. Transient anxiety elicits appropriate responses to protect the body ([@bib1000]). Anxiety disorders are a common group of mental disorders, characterized by long-lasting anxiety, which is accompanied by a characteristic series of physiological and behavioral responses including vigilance, avoidance and arousal ([@bib0550]). According to the Diagnostic and Statistical Manual of the American Psychiatric Association, anxiety disorders are divided into six discrete categories including generalized anxiety disorder (GAD), social phobia, simple phobia, panic disorder, post-traumatic stress disorder, and obsessive compulsive disorder, among which GAD is the most highly prevalent. Cognitive behavioral therapy, benzodiazepines, buspirone, and antidepressants are common treatment of anxiety disorders in clinic.

A variety of molecular targets, including neurotransmitters and transcript factors, involved in anxiety, have been revealed ([@bib0550]). Benzodiazepines (BZPs), a type of classic medicine for treatment of anxiety enhance the effect of GABA at the GABA~A~ receptor, resulting in anxiolytic properties ([@bib1000]). The serotonergic system is extensively implicated in anxiety. Knockout of 5-HT~1A~ receptor leads to an anxiogenic phenotype and selective serotonin reuptake inhibitors (SSRIs) are used as the first-line compounds for clinical treatment of anxiety ([@bib0550]; [@bib0620]; [@bib1210]; [@bib0555]). Decreased level of CREB and neuropeptide Y system (NPY) are also implicated in anxiety-related behaviors ([@bib1490]; [@bib1150]). Moreover, a perturbation of glutamatergic transmission is implicated in affective disorders including anxious states ([@bib1015]).

The implication of NO in anxiety has been proposed by a series of studies ([@bib1370]; [@bib0845]; [@bib0575]). The distribution of neurons expressing NOS in brain areas such as the medial amygdala (MeA), the dorsolateral periaqueductal grey (dlPAG), the hypothalamus, and the hippocampus indicate potential function of NO in anxiety ([@bib1510]; [@bib0365]). Benzodiazepines (BZDs), such as diazepam, are a type of early found and classic anxiolytic drug ([@bib0550]; [@bib1450]). Acute administration of 7-NI, a typical nNOS inhibitor, resulted in anxiolysis similar to diazepam ([@bib0370]). Indeed, inhibition of nNOS activity by 7-NI treatment reduced anxiety-like responses to social stimuli in rodents ([@bib1595]; [@bib1515]). Mice lacking gene that encodes nNOS expressed abnormal anxiety levels compared to WT mice ([@bib1595]; [@bib0135]; [@bib1600]). It was demonstrated that the anxiolytic effect of nNOS inhibition was mediated by reduced production of NO in the brain ([@bib0740]). However, a serial of studies found that NO donor including sodium nitroprusside and molsidomine induced anxiolytic-like behavior ([@bib0745]; [@bib1465]). But it was not well demonstrated the effect was attributed to the generation of NO or the chemicals themselves. The interaction between NO and classic anxiolytic drugs also support an anxiolytic property of NO reduction. In our lab, Zhang et al found that repression of nNOS-NO pathway in the hippocampus accounts for the regulatory role of 5-HT~1A~ receptor by fluoxetine, producing anxiolytic effect ([@bib1655]). The neurosteroid dehydroepiandrosterone sulphate (DHEAS) exerted anxiolytic effect, which was potentiated by NO precursor L-arginine ([@bib1130]; [@bib0205]). In contrast, the anxiolytic effects of DHEAS were abolished by a type of NOS inhibitor, L-NAME, pretreatment \[[@bib0205]). Moreover, the anxiolytic effects of morphine were partially modulated by NO \[[@bib0365]; [@bib0735]). These evidences suggest suppression of NO generation exert anxiolytic-like effect. But it is not clear whether and how over-activity of nNOS-NO signaling plays an important role in the pathogenesis of anxiety, which will be discussed in the following paragraph.

Restraint stress can induce psychological and physical changes including anxiogenic-like behavior, endocrine dysfunction, and autonomic alterations in rodents ([@bib1225]; [@bib0170], [@bib0165]). Increased nNOS expression in the PFC and hippocampus is associated with stress-triggered anxiety states ([@bib1505]). Besides the expression level changes, interestingly, Zhu et al found that chronic mild stress caused augment of nNOS-CAPON-Dexras 1 complex in the hippocampus ([@bib1710]). Consequently, the nNOS-CAPON association led to a large amount of NO generation, resulting in a high level of S-ntriosyation of Dexras 1 binding to CAPON ([Fig. 4](#fig0020){ref-type="fig"}). After S-nitrosylation, Dexras 1 down-regulated ERK phosphorylation, thereby causing anxiogenic-like phenotype ([@bib1710]). Recently, we found that this mechanism mediated the effect of NF-κB in stress-induced anxiety behaviors ([@bib1715]). Decreased 5-HT in the hippocampus after stress contributes to the etiology of anxiety. Silencing of 5-HTR1 A signaling up-regulated the expression of nNOS in the hippocampus, regulating anxiety-related behaviors ([@bib1655]). The nNOS-NO pathway have strong suppressive effect on ERK phosphorylation ([@bib0175]). Collectively, the dysfunction of 5-HTR1 A and the excessive coupling of nNOS with CAPON have similar biological end mediating the pathology of anxiety behavior ([Fig. 4](#fig0020){ref-type="fig"}). However, ERK has common and wide biological effects, rendering it not a satisfactory target for drug discovery. The disruption of nNOS : CAPON interaction only modulate ERK in certain pathway in specific cells, might representing a suitable drug target for anxiety treatment and other neuronal diseases ([@bib0885]).Fig. 4Novel target for treatment of anxiety: nNOS-CAPON.Fig. 4

Chronic mild stress augments the nNOS-CAPON-Dexras 1 complex, repressing the phosphorylation of ERK. Disruption of the association of nNOS and CAPON reverses this process and exerts an anxiolytic effect. Fluoxetine produces anxiolytic function through down-regulating the expression of nNOS and CREB activity.

Conclusions and perspectives {#sec0070}
============================

In summary, nNOS is closely implicated in a wide range of pathologies and molecular mechanisms of affective disorders. The expression of nNOS in the CNS is widely distributed. In the hippocampus, nNOS tightly correlates with MDD and anxiety while the function of nNOS in the LC in the pathology of BPD attracts more attention. Besides, the role of nNOS in other places such as the cortex, hypothalamus, and dorsal raphe, *etc*. in the pathophysiology of affective disorders is also very important. Thus, we are still at the starting line for understanding the full roles of nNOS in modulating motion and mood. Due to the impairment of memory formation after nNOS activity inhibition, the development of drugs for curing affective disorders is limited. Fortunately, uncoupling nNOS--PSD95 and nNOS-CAPON interactions did not cause this severe side effect. We believe that after further understanding of nNOS and its signaling mechanism and the expected development of new technologies, nNOS will be an important target for treatment and cure of affective disorders.
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